StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)

Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –

Regeneron Pharmaceuticals CEO Annual Total Compensation [annual] by Year

CEO (President & CEO) Annual Total Compensation [annual] ($) ($)

Regeneron Pharmaceuticals CEO Annual Total Compensation [annual]: $7,280,549 in FY2025, up 6.7% from a year earlier.

Latest, FY2025
7,280,549
Period ended Dec 31, 2025
Change on a year earlier
+6.7%
6,823,034 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below

Where the FY2025 figure comes from

“The total 2025 compensation of Dr. Schleifer, as reported in the Summary Compensation Table above, was $ 7,280,549.”

Source: Proxy Statement (DEF 14A) (regn-20260424.htm, filed 2026-04-24) ↗

Reported in DEF 14A Proxy Statements — CEO Pay Ratio Disclosure.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCEO (President & CEO) Annual Total Compensation [annual] ($) ($)Year on yearSource
FY2025Dec 31, 20257,280,549+6.7%Proxy Statement (DEF 14A) (regn-20260424.htm, filed 2026-04-24) ↗
FY2024Dec 31, 20246,823,034-16.6%Proxy Statement (DEF 14A) (regn013211-def14a.htm, filed 2025-04-29) ↗
FY2023Dec 31, 20238,184,338+16.9%Proxy Statement (DEF 14A) (lregn2024_def14a.htm, filed 2024-04-25) ↗
FY2022Dec 31, 20227,004,069+8.2%Proxy Statement (DEF 14A) (lregn2023_def14a.htm, filed 2023-04-21) ↗
FY2021Dec 31, 20216,470,514-95.2%Proxy Statement (DEF 14A) (c102797_def14a.htm, filed 2022-04-21) ↗
FY2020Dec 31, 2020135,350,121+530.9%Proxy Statement (DEF 14A) (c101011_def14a.htm, filed 2021-04-23) ↗
FY2019Dec 31, 201921,455,117–Proxy Statement (DEF 14A) (c95145_def14a.htm, filed 2020-04-24) ↗

Cite this data

StockData. (2026). Regeneron Pharmaceuticals CEO Annual Total Compensation [annual] ($), annual FY2019–FY2025 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/proxy-ceo-comp

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?